Clinical Trial Update: Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection [Phase 2]

View source ↗

Summary

Extension phase 2 trial of ARC-520 for chronic Hepatitis B was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ARC-520

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Hepatitis B | Phase 2 | Status: TERMINATED | Results posted: 2019-04-16